A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Trial Profile

A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Venetoclax (Primary) ; Cobimetinib; Idasanutlin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 Nov 2017 According to a Genentech media release, data from the study will be presented at the American Society of Hematology (ASH) 2017 Annual Meeting.
    • 26 Oct 2017 Planned End Date changed from 31 Jul 2019 to 15 Jan 2020.
    • 26 Oct 2017 Planned primary completion date changed from 30 Sep 2017 to 15 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top